Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics names Moncef Slaoui as Chair Designate
Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...
Mena FN1mon
Abzena Strengthens Board With Appointment Of Biopharma Industry Leader, Dr Moncef Slaoui
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors. A highly ...
Business Wire7d
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...
Investing7d
Arcturus Therapeutics names Moncef Slaoui as Chair Designate
SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui ...